XPD could suppress growth of HepG2.2.15 and down-regulate the expression of hepatitis B virus x protein through P53 pathway

Biochemical and Biophysical Research Communications

Volumn 419, Issue 4, 2012, Pages 761-767

  Ding, Hao ^a,b   Xu, Jiang jing ^b   Huang, Yuan ^a   Du, Fang teng ^a   Zhang, Ji xiang ^a,b  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Provincial Key Laboratory of Molecular Medicine   (China)

Author keywords

Apoptosis; Hepatitis B virus X protein; Hepatoma cells; P53; Xeroderma pigmentosum D

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HEPATITIS B VIRUS X PROTEIN; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SERINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

APOPTOSIS; ARTICLE; ASSAY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL STRAIN HEPG2; CELL VIABILITY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BCL-2-ASSOCIATED X PROTEIN; BENZOTHIAZOLES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); TOLUENE; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

HEPATITIS B VIRUS;

EID: 84862822055     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.097     Document Type: Article

References (35)

1. Sung P., Bailly V., Weber C., Thompson L.H., Prakash L., Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993, 365(6449):852-855.
2. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Trans cription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002, 62(17):4899-4902.
3. Rudolf J., Rouillon C., Schwarz-Linek U., White M.F. The helicase XPD unwinds bubble structures and is not stalled by DNA lesions removed by the nucleotide excision repair pathway. Nucleic Acids Res. 2010, 38(3):931-941.
4. Emmert S., Leibeling D., Rünger T.M. Syndromes with genetic instability: model diseases for (skin) cancerogenesis. J. Dtsch. Dermatol. Ges. 2006, 4(9):721-731.
5. H.P. Yu, X.L. Wang, X. Sun Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma, Cancer Genet. Cytogenet. 154 (1) (2004) 10-15.
6. Zhang J., Powell S.N. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res. 2005, 3(10):531-539.
7. Nakajima S., Lan L., Kanno S., Takao M., Yamamoto K., Eker A.P., Yasui A. UV light-induced DNA damage and tolerance for the survival of nucleotide excision repair-deficient human cells. J. Biol. Chem. 2004, 279(45):46674-46677.
8. Lehmann A.R. DNA repair-deficient diseases, xeroderma pigmentosum. Cockayne syndrome and trichothiodystrophy. Biochimie 2003, 85(11):1101-1111.
9. Lainé J.P., Mocquet V., Bonfanti M., Braun C., Egly J.M., Brousset P. Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair (Amst) 2007, 6(9):1264-1270.
10. Coin F., Marinoni J.C., Rodolfo C., Fribourg S., Pedrini A.M., Egly J.M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nature Genet. 1998, 20(2):184-188.
11. Robles A.I., Harris C.C. P53-mediated apoptosis and genomic instability diseases. Acta Oncol. 2001, 40(6):696-701.
12. Askin D.F., Diehl-Jones W.L. The neonatal liver: part III: pathophysiology of liver dysfunction. Neonatal Netw. 2003, 22(3):5-15.
13. Becker S.A., Lee T.H., Butel J.S., Slagle B.L. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 1998, 72(1):266-272.
14. Jaitovich-Groisman I., Benlimame N., Slagle B.L., Perez M.H., Alpert L., Song D.J., Fotouhi-Ardakani N., Galipeau J., Alaoui-Jamali M.A. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J. Biol. Chem. 2001, 276(17):14124-14132.
15. H.Y. Wang, G.F. Xiong, J.X. Zhang, H. Xu , W.H. Guo, J.J. Xu, X.Y. Xiong. The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells. Med. Oncol., 2011 Jan 25.
16. Goldstein I., Marcel V., Olivier M., Oren M., Rotter V., Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011, 18(1):2-11.
17. X.W. Wang, W. Vermeulen, J.D. Coursen, M. Gibson, S.E. Lupold, K. Forrester, G. Xu, L. Elmore, H. Yeh, J.H. Hoeijmakers, C.C. Harris. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway, Genes Dev., 10(10) (1996) 1219-1232.
18. Robles A.I., Wang X.W., Harris C.C. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene 1999, 18(33):4681-4688.
19. Clément V., Dunand-Sauthier I., Clarkson S.G. Suppression of UV-induced apoptosis by the human DNA repair protein XPG. Cell Death Differ. 2006, 13(3):478-488.
20. Wang X.W., Gibson M.K., Vermeulen W., Yeh H., Forrester K., Stürzbecher H.W., Hoeijmakers J.H., Harris C.C. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995, 55(24):6012-6016.
21. Yu J., Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 2005, 331(3):851-858.
22. Schuler M., Green D.R. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans. 2001, 29(Pt 6):684-688.
23. Kokkinakis D.M. Methionine-stress: a pleiotropic approach in enhancing the efficacy of chemotherapy. Cancer Lett. 2006, 233(2):195-207.
24. Sells M.A., Chen M.L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 1987, 84(4):1005-1009.
25. Wu K.L., Zhang X., Zhang J., Yang Y., Mu Y.X., Liu M., Lu L., Li Y., Zhu Y., Wu J. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res. 2005, 112(1-2):100-107.
26. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285(5434):1733-1737.
27. Javelaud D., Besancon F. Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J. Biol. Chem. 2002, 277(40):37949-37954.
28. Fogarty M.P., McCormack R.M., Noonan J., Murphy D., Gowran A., Campbell V.A. A role for p53 in the beta-amyloid-mediated regulation of the lysosomal system. Neurobiol. Aging 2010, 31(10):1774-1786.
29. Chua C.C., Liu X., Gao J., Hamdy R.C., Chua B.H. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(6):H2606-H2613.
30. Rowland B.D., Peeper D.S. KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 2006, 6(1):11-23.
31. Del Principe M.I., Del Poeta G., Venditti A., Buccisano F., Maurillo L., Mazzone C., Bruno A., Neri B. Irno Consalvo M, Lo Coco F, Amadori S. Apoptosis and immaturity in acute myeloid leukemia. Hematology 2005, 10(1):25-34.
32. De Mitri M.S., Cassini R., Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur. J. Cancer 2010, 46(12):2178-2186.
33. Thapa D., Babu D., Park M.A., Kwak M.K., Lee Y.R., Kim J.M., Kwon T.K., Kim J.A. Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells. Biochem. Pharmacol. 2010, 80(1):62-71.
34. Kelly K.J., Plotkin Z., Vulgamott S.L., Dagher P.C. P53 Mediates the Apoptotic Response to GTP Depletion after Renal Ischemia-Reperfusion: Protective Role of a p53 Inhibitor. J. Am. Soc. Nephrol. 2003, 14(1):128-138.
35. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26(15):2166-2176.